Downstaging in patients with hepatocellular carcinoma: Is there real hope?

Aim: The conventional criteria preclude many patients with hepatocelular carcinom (HCC) from liver transplantation (LT). Recentstudies reported comparable results in downstaged patients. In present study, the outcomes of patients with HCC after LT wasevaluated in regard to response to a uniform downstaging protocol.Materials and Methods: The data of 136 HCC patients who underwent LT between January 2012 and April 2018 were analysed. 82patients who were with minimum follow-up of one year and/or who reached the end-point (recurrence and/or death) were enrolledto the study and were divided into two groups as downstaging group and initially within Milan group. We retrospectively collectedand then compared the baseline characteristics, postoperative complications, survival rate, and tumor recurrence rate of patients.Results: One of the study group included 54 (45.7%) patients within Milan criteria initially and there were 28 (23.7%) patients in thedownstaging group. The disease-free survival rates were 82.1% and 87.1% in downstaging group and initially witihin Milan group,respectively (p=0.368). The overall 3-year survival rates were 82.1% and 88.9% in downstaging group and intially within Milan group,respectively (p=0.402).Conclusion: The patients who were initially excluded according to the current conventional criteria had a chance for LT withcomparable outcome according to both the overall survival and disease-free survival rates.

PDF

___

1. Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit?. Transl Gastroenterol Hepatol. 2017;2:106-19.
2. Sharr WW, Chan SC, Lo CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation 2014;97:10-7.
3. Toso C, Mentha G, Kneteman NM, et al. The place of downstaging for hepatocellular carcinoma. J Hepatol 2010;52:930-6.
4. Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015;61:1968-77.
5. Gordon-Weeks AN, Snaith A, Petrinic T, et al. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg 2011;98:1201-8.
6. Györi GP, Felsenreich DM, Silberhumer GR, et al. Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation. Eur Surg 2017;49:236-43.
7. Lei J, Wang W, Yan L. Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria. J Gastrointest Surg 2013;17:1440-6.
8. Pompili M, Francica G, Ponziani FR, et al. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013 21;19:7515-30.
9. Pommergaard HC, Rostved AA, Adam R, et al. Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transpl Int 2018;31:531-9.
10. Lai Q, Avolio AW, Graziadei I, et al. α-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013;19:1108-18.
11. Chapman WC, Garcia-Aroz S, Vachharajani N, et al. Liver Transplantation for advanced hepatocellular carcinoma after downstaging without up-front stage restrictions. J Am Coll Surg 2017;224:610-21.
12. Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008;8:2547-57.
13. Kim Y, Stahl CC, Makramalla A, et al. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. Surgery 2017;162:1250-8.
14. Mehta N, Guy J, Frenette CT, et al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol 2018;16:955-64.
15. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant 2018;18:1206-13.
16. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J et al. Metroticket 2,0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018;154:128-39.